congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Dato-DXd
ELCC 2024 | March 20-23, 2024
Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC) – nonsquamous (NSQ) histology in the phase 3 TROPION-Lung01 Trial
Poster
HER3-DXd
ELCC 2024 | March 20-23, 2024
Patritumab deruxtecan (HER3-DXd) in previously treated patients with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01